Invus Public Equities, L.P.

CIK 1340097 · last filed 2024-12-12

Invus Public Equities, L.P. is a corporate insider who has filed 9 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider sold $333.2M of SRRK on Dec 12, 2024. Across all open-market trades the lifetime net is −$307.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $488.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$488.29M

Companies

3

Total Filings

9

Lifetime Open-Market Net

-$307.87M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
SRRK	10%+ Owner	9,700,005	$49.10	$476.27M	-$160.57M	5	2024-12-12
CRESCENT BIOPHARMA, INC. (GLYC) Delisted	10%+ Owner	66,957	$15.70	$1.05M	-$1.49M	3	2024-08-07
SEER	10%+ Owner	5,588,366	$2.15	$12.01M	-$145.81M	1	2021-02-03

Recent Filings

9 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2024-12-12	SRRK	Sell (S)	−8,000,000	-$333.20M	EDGAR
2024-08-07	CRESCENT BIOPHARMA, INC. (GLYC) Delisted	Sell (S)	−1,101,275	-$205.9K	EDGAR
2024-07-30	CRESCENT BIOPHARMA, INC. (GLYC) Delisted	Sell (S)	−6,895,595	-$1.58M	EDGAR
2023-10-16	SRRK	Buy (P)	+17,599,448	$120.69M	EDGAR
2023-05-02	SRRK	Buy (P)	+252,456	$1.62M	EDGAR
2023-02-13	CRESCENT BIOPHARMA, INC. (GLYC) Delisted	Buy (P)	+91,608	$297.0K	EDGAR
2023-01-11	SRRK	Sell (S)	−8,752	-$83.0K	EDGAR
2021-02-03	SEER	Sell (S)	−2,272,905	-$145.81M	EDGAR
2018-05-31	SRRK	Mixed	+19,168,320	$50.40M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.